JCR Pharmaceuticals Co., Ltd. (4552) Price & Analysis

Compare

1 Followers

4552 Stock Chart & Stats

¥712.00

-¥21.00(-3.43%)

At close: Jan 08 4:00 PM EST

¥712.00

-¥21.00(-3.43%)

Day’s Range― - ―

52-Week Range¥386.00 - ¥824.00

Previous CloseN/A

Volume326.50K

Average Volume (3M)578.69K

Market Cap

¥81.55B

Enterprise Value¥117.36B

Total Cash (Recent Filing)¥13.18B

Total Debt (Recent Filing)¥40.10B

Price to Earnings (P/E)―

Beta0.81

Next Earnings

May 07, 2026

EPS Estimate

-1.14

Next Dividend Ex-DateN/A

Dividend Yield2.71%

Share Statistics

EPS (TTM)0.27

Shares Outstanding129,686,310

10 Day Avg. Volume668,090

30 Day Avg. Volume578,686

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)1.27

Price to Sales (P/S)1.81

P/FCF Ratio-3.90

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

¥710.00

Price Target Upside-0.28% Downside

Rating ConsensusHold

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Rare-disease And Advanced Biologics FocusA strategic focus on rare diseases and advanced biologics creates durable competitive advantages: high clinical barriers, pricing power, and concentrated patient populations that support predictable, long-duration revenue streams and justify sustained R&D investment over months to years.

Manufacturing Capabilities And Collaboration Revenue ModelIn-house biologics manufacturing plus a mixed revenue model (product sales, manufacturing contracts, and partnership milestones/royalties) diversifies cash sources, strengthens partner ties, and supports recurring non-product revenue that can smooth cycles and fund development over the medium term.

Stable Equity Base And Positive Recent Revenue GrowthA healthy equity ratio provides a solvency buffer while modest positive revenue growth indicates demand resilience. Together they give the firm capacity to absorb shocks, maintain R&D spending, and pursue partnerships without immediate solvency risk over the next several months.

Bears Say

Negative Operating And Free Cash FlowSustained negative operating and free cash flow undermines the company’s ability to internally fund costly biologics development and manufacturing. Over months this raises reliance on external financing, increasing dilution or interest burden and constraining strategic flexibility.

Rising Total Debt And Higher LeverageAn increasing debt load raises fixed obligations and reduces balance sheet flexibility. For a development-heavy biotech, rising leverage can elevate refinancing risk, limit capacity for new partnerships or capex, and increase vulnerability to funding market conditions over the medium term.

Negative Profitability And Collapsed EPSNegative margins and a dramatic EPS decline signal persistent operational inefficiencies or one-off setbacks. Over 2–6 months this impairs retained earnings, threatens dividend sustainability, and can weaken negotiating leverage with partners and payers for pricing or milestone payments.

JCR Pharmaceuticals Co., Ltd. News

JCR Pharmaceuticals Swings Back to Profit and Lifts Full-Year Outlook

JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) just unveiled an announcement. JCR Pharmaceuticals reported a sharp turnaround in...

20d ago

4552

JCR Books ¥1.88 Billion Government Subsidy as Extraordinary Income for Q3 FY2025

An update from JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) is now available. JCR Pharmaceuticals has recognized ¥1.882...

20d ago

4552

JCR Pharmaceuticals Issues FY2025 Q3 Results Briefing With Caution on Outlook

JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) has issued an update. JCR Pharmaceuticals has released materials for its...

20d ago

4552

JCR Pharmaceuticals Lifts Sales Outlook but Slashes Profit Forecast on Higher R&D and Costs

JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) has shared an announcement. JCR Pharmaceuticals has revised its consolidated forecast...

20d ago

4552

JCR Pharmaceuticals Briefs Investors on New Agreement with Italfarmaco

JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) has shared an update. JCR Pharmaceuticals has held a briefing session...

25d ago

4552

JCR Pharmaceuticals Strikes Exclusive Japan Deal With Italfarmaco for DMD Drug Givinostat

JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) has provided an update. JCR Pharmaceuticals and Italy’s Italfarmaco have signed...

2M ago

4552

JCR Pharmaceuticals Reports Strong Financial Recovery in First Half of FY2025

The latest update is out from JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ). JCR Pharmaceuticals reported a significant...

4M ago

4552

JCR Pharmaceuticals’ JR-141 Study: A Promising Update for Hunter Syndrome Treatment

JCR Pharmaceuticals Co., Ltd. (($JP:4552)) announced an update on their ongoing clinical study. JCR Pharmaceuticals Co., Ltd. is...

4M ago

4552

JCR Pharmaceuticals Advances in MPS IIIB Treatment with JR-446 Study

JCR Pharmaceuticals Co., Ltd. (($JP:4552)) announced an update on their ongoing clinical study. JCR Pharmaceuticals Co., Ltd. is...

4M ago

4552

JCR Pharmaceuticals Reports Q1 FY2025 Financial Results with Positive Sales Growth

JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) has shared an update. JCR Pharmaceuticals reported its consolidated financial results...

7M ago

4552

4552 FAQ

What was JCR Pharmaceuticals Co., Ltd.’s price range in the past 12 months?

JCR Pharmaceuticals Co., Ltd. lowest stock price was ¥386.00 and its highest was ¥824.00 in the past 12 months.

What is JCR Pharmaceuticals Co., Ltd.’s market cap?

JCR Pharmaceuticals Co., Ltd.’s market cap is ¥81.55B.

When is JCR Pharmaceuticals Co., Ltd.’s upcoming earnings report date?

JCR Pharmaceuticals Co., Ltd.’s upcoming earnings report date is May 07, 2026 which is in 79 days.

How were JCR Pharmaceuticals Co., Ltd.’s earnings last quarter?

JCR Pharmaceuticals Co., Ltd. released its earnings results on Jan 28, 2026. The company reported ¥0.27 earnings per share for the quarter, beating the consensus estimate of -¥1.072 by ¥1.342.

Is JCR Pharmaceuticals Co., Ltd. overvalued?

According to Wall Street analysts JCR Pharmaceuticals Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does JCR Pharmaceuticals Co., Ltd. pay dividends?

JCR Pharmaceuticals Co., Ltd. pays a Semiannually dividend of ¥10 which represents an annual dividend yield of 2.71%. See more information on JCR Pharmaceuticals Co., Ltd. dividends here

What is JCR Pharmaceuticals Co., Ltd.’s EPS estimate?

JCR Pharmaceuticals Co., Ltd.’s EPS estimate is -1.14.

How many shares outstanding does JCR Pharmaceuticals Co., Ltd. have?

JCR Pharmaceuticals Co., Ltd. has 129,686,310 shares outstanding.

What happened to JCR Pharmaceuticals Co., Ltd.’s price movement after its last earnings report?

JCR Pharmaceuticals Co., Ltd. reported an EPS of ¥0.27 in its last earnings report, beating expectations of -¥1.072. Following the earnings report the stock price went down -2.519%.

Which hedge fund is a major shareholder of JCR Pharmaceuticals Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4552

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.

JCR Pharmaceuticals Co., Ltd. (4552) Earnings & Revenues

Historic Earnings Reports

4552 Stock 12 Month Forecast

Average Price Target

¥710.00

▼(-0.28% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"483":"¥483","553":"¥553","623":"¥623","693":"¥693","763":"¥763"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":750,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥750.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":710,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥710.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":670,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥670.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[483,553,623,693,763],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,606,617.0769230769231,628.1538461538462,639.2307692307693,650.3076923076923,661.3846153846154,672.4615384615385,683.5384615384615,694.6153846153846,705.6923076923077,716.7692307692307,727.8461538461538,738.9230769230769,{"y":750,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,606,614,622,630,638,646,654,662,670,678,686,694,702,{"y":710,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,606,610.9230769230769,615.8461538461538,620.7692307692307,625.6923076923077,630.6153846153846,635.5384615384615,640.4615384615385,645.3846153846154,650.3076923076923,655.2307692307693,660.1538461538462,665.0769230769231,{"y":670,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":534.44,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":484.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":490.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":489.25,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":609.34,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":502.04,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":590.64,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":625.09,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":634,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":598,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":762,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":712,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":606,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >